About Us

about hypgen

Overview

HypGen Inc is a publicly traded biotechnology company focused on the development and commercialization of Phorbol 12-myristate 13-acetate (PMA) internal i.d. RP-323, a focused immunotherapy and stem cell activator for treating neurological diseases (CNS). Company goals are to advance clinical development; expand the company’s pipeline; form a development partnership with a bio-pharmaceutical or major-pharmaceutical company; while taking the company through a go-public transaction. The go-public transaction is complete.

A phase I safety study has been completed and the company is now prepared to enter into phase I/II clinical study in Parkinson’s disease in collaboration with a major University Hospital in Atlanta Georgia.

Parkinson’s Disease

Parkinson’s disease is a progressive, degenerative neurological disease affecting 1 in 500 people. It is believed that between 7 to 10 million people worldwide are affected and that 60,000 new cases are diagnosed annually in the United States alone. It results from degeneration of neurons in a region of the brain that controls movement. Though the specific cause is unknown (idiopathic) in 85% of the cases, 15% of cases are considered to be from a genetic basis. The main pathologic feature of Parkinson’s disease is degeneration of dopaminergic cells in the basal ganglia, especially in the substantia nigra. This loss of cells leads to progressive decrease in nerve control over both movement (motor symptoms i.e. tremor, slowness of movement, imbalance) as well as non-motor symptoms (constipation, insomnia, vision problems).

According to The Parkinson’s Disease Foundation, the combined cost of Parkinson’s, including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone. Medication costs for an individual person with Parkinson’s disease average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient. According to the Centers for Disease Control (CDC), complications due to Parkinson’s disease is the 14th leading cause of death in the United States

The Market

The market for treatment of Parkinson’s disease is excess of $10 billion annually.

Patents

Parkinson’s Disease
Stroke